RT @SFDiabete: Dans l’étude EMPA-REG OUTCOME®, la réduction de la mortalité CV, des hospitalisations pour insuffisance cardiaque, de l’appa…
RT @SFDiabete: Dans l’étude EMPA-REG OUTCOME®, la réduction de la mortalité CV, des hospitalisations pour insuffisance cardiaque, de l’appa…
RT @SFDiabete: Dans l’étude EMPA-REG OUTCOME®, la réduction de la mortalité CV, des hospitalisations pour insuffisance cardiaque, de l’appa…
Dans l’étude EMPA-REG OUTCOME®, la réduction de la mortalité CV, des hospitalisations pour insuffisance cardiaque, de l’apparition ou de l’aggravation d’une néphropathie sous empaglifozine étaient identiques chez les hommes et chez les femmes. https://t.co
RT @DiabetologiaJnl: #toptweet this week! Reductions in risk of CV death and HF hospitalisations by #empagliflozin in EMPA-REG OUTCOME® wer…
RT @DiabetologiaJnl: #toptweet this week! Reductions in risk of CV death and HF hospitalisations by #empagliflozin in EMPA-REG OUTCOME® wer…
RT @DiabetologiaJnl: #toptweet this week! Reductions in risk of CV death and HF hospitalisations by #empagliflozin in EMPA-REG OUTCOME® wer…
RT @DiabetologiaJnl: #toptweet this week! Reductions in risk of CV death and HF hospitalisations by #empagliflozin in EMPA-REG OUTCOME® wer…
#toptweet this week! Reductions in risk of CV death and HF hospitalisations by #empagliflozin in EMPA-REG OUTCOME® were not different between women and men. #T2D #cardiovascular #heartfailure #GoRedForWomen https://t.co/YCXxMhD9oZ
RT @DiabetologiaJnl: Reductions in risk of CV death and HF hospitalisations by #empagliflozin in EMPA-REG OUTCOME® were not different betwe…
RT @DiabetologiaJnl: Reductions in risk of CV death and HF hospitalisations by #empagliflozin in EMPA-REG OUTCOME® were not different betwe…
RT @DiabetologiaJnl: Reductions in risk of CV death and HF hospitalisations by #empagliflozin in EMPA-REG OUTCOME® were not different betwe…
RT @DiabetologiaJnl: Reductions in risk of CV death and HF hospitalisations by #empagliflozin in EMPA-REG OUTCOME® were not different betwe…
RT @DiabetologiaJnl: Reductions in risk of CV death and HF hospitalisations by #empagliflozin in EMPA-REG OUTCOME® were not different betwe…
RT @DiabetologiaJnl: Reductions in risk of CV death and HF hospitalisations by #empagliflozin in EMPA-REG OUTCOME® were not different betwe…
RT @DiabetologiaJnl: Reductions in risk of CV death and HF hospitalisations by #empagliflozin in EMPA-REG OUTCOME® were not different betwe…
RT @DiabetologiaJnl: Reductions in risk of CV death and HF hospitalisations by #empagliflozin in EMPA-REG OUTCOME® were not different betwe…
Reductions in risk of CV death and HF hospitalisations by #empagliflozin in EMPA-REG OUTCOME® were not different between women and men. #T2D #cardiovascular #heartfailure #GoRedForWomen https://t.co/YCXxMhD9oZ https://t.co/s8Y68t7FWw
RT @DanielJDrucker: The Women of EMPA-REG OUTCOME #diabetes Lower Incidence Rates Similar Benefits in Reduction of MACE Outcomes #CVD @Diab…
RT @DanielJDrucker: The Women of EMPA-REG OUTCOME #diabetes Lower Incidence Rates Similar Benefits in Reduction of MACE Outcomes #CVD @Diab…
RT @DanielJDrucker: The Women of EMPA-REG OUTCOME #diabetes Lower Incidence Rates Similar Benefits in Reduction of MACE Outcomes #CVD @Diab…
RT @DanielJDrucker: The Women of EMPA-REG OUTCOME #diabetes Lower Incidence Rates Similar Benefits in Reduction of MACE Outcomes #CVD @Diab…
RT @DanielJDrucker: The Women of EMPA-REG OUTCOME #diabetes Lower Incidence Rates Similar Benefits in Reduction of MACE Outcomes #CVD @Diab…
The Women of EMPA-REG OUTCOME #diabetes Lower Incidence Rates Similar Benefits in Reduction of MACE Outcomes #CVD @DiabetologiaJnl https://t.co/inIAestjYz